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Abstract 
The hypothesis is that cell therapy with autologous keratinocytes promotes healing of chronic venous ulcers that failed to 
respond to other forms of treatment. This is a randomized study in which 31 patients with chronic venous ulcers participated, 
totaling 38 venous ulcers. Thirty one ulcers were included in Group 1 (G1) treated with autologous keratinocytes applied at the 
ulcers’ base with autologous fibrin scaffold. Group 2 (G2) included 7 ulcers treated with autologous fibrin glue only. The ulcers 
were evaluated with digital photography and computer image analysis [area and wound healing rate (WHR)] over 90 days. The 
duration of ulcers from the G1 was 118 months on average and in G2 the average was 114 months without any difference. In 
relation to the initial size of ulcers, both groups were similar considering the mean, SD and median respectively: G1 (18; 27; 5.6 
cm2) and G2 (19.5; 0.11; 0.29 cm2). The medians of WHR in G1 and G2 have got significant differences between groups. 
Considering only the wounds that reached WHR larger than 0.4 (40% rate of healing), in the G1, 29% of ulcers reached it at  
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the 30th day, 58% at  the 45th, 77% at the 60th, 84% at  the 75th and 90% at the 90th day while in the G2 only 14% (one ulcer) 
reached it at the 30th day remaining steady until the 90th day when only one more ulcer reached this rate (28.6%). The median of 
procedures was 2 for G1 and 3 for G2. These findings showed the relevant efficacy of cell therapy with autologous 
keratinocytes applied with autologous fibrin glue scaffold achieving high rates of healing from the thirtieth day of follow-up 
and becoming larger by the ninetieth day. In contrast, the autologous fibrin glue applied lonely in G2 did not improve the 
wound healing significantly. The cell therapy with autologous keratinocytes applied with autologous fibrin scaffold promotes 
greater healing of chronic venous ulcers than autologous fibrin glue only, particularly large recalcitrant ulcers that do not 
respond to conventional treatment. 
© 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license. 
Selection and peer-review under responsibility of the Centre for Rapid and Sustainable Product Development, Polytechnic 
Institute of Leiria, Centro Empresarial da Marinha Grande. 
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1. Introduction 
Leg ulcers are characterized by circumscribed or irregular loss of the epidermis of the lower limbs and possibly 
the dermis and subcutaneous tissue. It has many different pathogenic mechanisms and is frequently caused by 
diabetes mellitus, cardiac insufficiency and chronic venous hypertension complications. They can also be caused 
by autoimmune diseases and local infections. A total of 75% of lower limb ulcers are venous ulcers, which means 
that they are caused by a chronic venous insufficiency due to superficial and deep veins abnormal function [1]. 
According to Van Bemmelen et al. the presence of multiple refluxing foot vein segments is often associated with 
forefoot and toe ulceration [2]. Lower limb ulcers, secondary to chronic venous disease in European and Western 
populations, are estimated to be from 0,5 to 1% prevalent. In the United Kingdom, 1,3% of the health budget is 
spent on venous ulcers. Tassiopoulos et al. analysed thirteen studies that included 1249 ulcerated limb. Of all these 
ulcerated limbs, reflux was seen in 1153 limbs (92%) [3]. 
Frade et al. evaluated 124 patients with leg ulcers in Juiz de Fora (Minas Gerais – Brazil), analysing their 
clinical and epidemiological profile. The average age was 62,6 years old and 65,3% were female. The venous 
insufficiency, Systemic arterial hypertension and diabetes mellitus were associated with the leg ulcers in 74,2%, 
51,6% and 20,2% of the cases,  respectively. Therefore, 67,8% of the wounds were classified as venous ulcers. 
They were located mainly on the distal third segment of legs, 40% of them were considered as medium size (2-
5cm) and 35,6% as large size (ulcers larger than 5cm) [4]. 
In this matter, venous ulcers are an important public health issue for many developed and developeding 
countries when taking in consideration the increase in life expectancy of the world’s population. With its increase, 
there will also be an increase of diseases associated with ulcers, such as chronic venous insufficiency, cardiac 
insufficiency and diabetes mellitus. Therefore, in the coming years, a higher incidence of venous ulcers is 
expected.  
This study tested the hypothesis that cell therapy with autologous keratinocytes applied with autologous fibrin 
glue promotes faster healing of chronic venous ulcers that failed to respond to other forms of treatment.  
2. Materials and Methods 
This is a case-controlled randomized study. 
2.1. Patients and ulcers 
A total of 31 patients with chronic venous ulcers were selected randomly from the Vascular Surgery Outpatient 
Clinic of the University of Campinas’ Clinical Hospital (Campinas, Brazil) and from the Ribeirão Preto’s Clinical 
Hospital’s Neurovascular Ulcers Outpatient Clinic (Ribeirão Preto, Brazil). These patients were selected 
considering the clinical aspects of venous damage diagnosed by surgeons and dermatologists. The treatments 
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started after the patients signed the informed consent term, approved by the Ethical Committee of the University of 
Campinas’ Clinical Hospital  (Protocol number 0076/2001).  
2.2. Groups 
Thirty eight ulcers were selected for treatment and follow up. Thirty one of these ulcers were included in group 
one (G1) and were treated with autologous keratinocytes applied with autologous fibrin glue. The other seven 
ulcers were included in group 2 (G2) and were treated with autologous fibrin glue only.  
2.3. Surgical procedures 
After local anesthesia, 1cm2 samples of skin from the inguinal region of the patients were taken in order to form 
keratinocytes culture. 
2.4. Cell culture 
According to Rehder et al., the skin fragments were placed on Petri dishes with trypsin 2,5% and  
Ethylenediamine tetraacetic acid (EDTA) 0,1% (Trypsin EDTA – GIBCO cat. 25200-056) and then were kept in 
incubator at 37oC with 5% of CO2 tension for 3 hours, followed by dermal-epidermal separation. Trypsin was then 
neutralized with serum collected from the patient and the mixture was filtered. The filtrate contained the skin cells 
and was centrifuged at 1.200 rotations per minute (rpm) for 10 minutes. After cell count, the cells were distributed 
in culture bottles (1x105 cells/cm2) with keratinocyte culture medium supplemented with 10% of serum collected 
from the patient. The culture bottles were then incubated at 37oC with 5% CO2 tension. The culture medium was 
changed three times a week. When the cells reached confluence, cell passage occurred. After 21 days there was a 
quantity of 10x106 keratinocytes [5].  
2.5. Fibrin Glue 
The autologous fibrin glue was prepared according to the technique described by Moraes et al.; venous blood 
was collected from each patient and placed in individual tubes containing 3,8% of sodium citrate (9:1). The plasma 
was obtained after centrifugation for 10 minutes at 3.000 rpm. Plasma fibrinogen was purified through the glycine 
precipitation technique. Autologous fibrin, calcium chloride (40mM) and autologous thrombin (300 IU) were 
applied concomitantly with cell cultures to the lesions [6].  
2.6. Patient treatment  
The G1 ulcers were covered with 2 mL of the cultivated keratinocyte cells applied with autologous fibrin glue 
(10x106 cells/mL) regardless of the wounded area. The G2 ulcers were treated only with 2 mL of autologous fibrin 
glue. Both groups received a framework of hardened plastic and nylon cover to avoid contact between the wound 
bed and the outside environment.  
2.7. Clinical follow-up by image 
The wounds were photographed every 15 days and analyzed by Image J software to calculate the wound area 
and the wound healing rate (WHR) over 90 days.  
WHR = (Ai-Af)/Ai  (1) 
Ai: Initial area; 
Af: Final area. 
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3. Results 
The patients were 61,5 years old on average (Standard Deviation=14.1; Median=63 years old). 24 of all 31 
patients were female and 7 were male, totaling 38 venous ulcers clinically characterized by specialists in vascular 
surgery and dermatology.  
The ulcers initial size was similar in both groups (p>0.05) and the average, the standard deviation (SD) and the 
median were 18; 27 and 5.6 cm2  respectively for G1. For G2, the average, the SD and the median were 19.5; 0.11  
and 0.29 cm2, respectively (figure 1A) 
The duration of the ulcers in the G1 was 118 months on average (SD=144 months; Median= 72 months). The 
duration of ulcers in the G2 was 114 months on average (SD=85 months; Median=96 months). There was 
practically no difference (p>0.05) as shown in figure 1B. 
 
 
Fig. 1. (a) Comparison between ulcers initial size in  G1 and G2 before treatment; (b) Comparison between the duration of the ulcers in months 
in  G1 and G2.  
During the follow up the ulcers treated with autologous keratinocytes and fibrin glue (Group 1) quickly formed 
a thick crust, which covered the wound bed. The crust formation was followed by wound reepithelization and 
therefore the ulcer size was reduced. The ulcers in G2 also formed a thick crust, but no reepithelization was 
detected (figure 2). 
 
 
Fig. 2. (a), (b), (c) and (d) G1’s patient follow up after treatment; (e), (f), (g) and (h) G2’s patient follow up after treatment. 
The medians of WHR for G1 were 0.28; 0.43; 0.60; 0.76 and  0.87; while for G2 they were 0.05; 0.14; 0.18; 
0.08 and 0.14 at the 30th, 45th, 60th, 75th and 90th  follow up day, respectively with significant differences between 
groups in all days with p=0.01; p=0.003; p=0.0004; p=0.0004; p=0.0001, respectively (figure 3). 
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Fig.3. G1 and G2’s WHR.  
Considering the effective treatment when the wounds reach WHR larger than 0.4 (40% healing rate) in group 
one 29% of the ulcers reached it at  the 30th day, 58% at the 45th , 77% at the 60th, 84% at the 75th and 90% at the 
90th day. In group 2 only 14% (one ulcer) reached it at the 30th day maintaining this WHR until the 75th day when 
only one more ulcer reached this rate. At the 90th day 14% had 40% of healing rate. The median of procedures was 
2 for G1 and 3 for G2 (figure 4). 
 
 
Fig. 4. Percentage of ulcers that reached at least 40% of wound healing rate.  
4. Discussion 
Nowadays, the cell therapy has shown an attractive alternative to treat skin wounds such as chronic venous 
ulcers. This form of therapy has been used to create skin substitutes [5, 7], aid wound healing, treat burns, among 
other purposes [8]. This technique could be used with autologous cells, which are cultured and expanded in vitro 
outside the body, and reused into the damaged place. The use of autologous cells may provide the minimization of 
risks from systemic immunological reactions, as well as disease transmission associated with grafts or cells that are 
not cultivated from the individual.  
To ensure the complete cell adhesion, autologous fibrin glue is commonly used. The development of tissue 
adhesives and sealants is a rapidly expanding area of clinical use. On the whole, the fibrin was recognized as the 
scaffold for tissue regeneration and the use of fibrin tampons was proposed to accelerate local hemostasis. 
As discussed by Valbonesi, tissue injury can cause the disruption of blood vessels that is responsible for 
extravasation of blood constituents and the first step of the process in the platelet activation after exposure of 
collagen. Platelets initiate clotting through the coagulation system. When thrombin is formed, fibrinogen is 
transformed into fibrin. This can be characterized as the real first step of wound healing. In addition, the fibrin glue 
reproduces this process and has been widely used in surgery to obtain hemostasis and expedite the process of 
wound healing [9]. 
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Our findings showed that the combination of the autologous keratinocytes with the autologous fibrin glue 
resulted in faster wound healing. This might have happened because of the increase of growth factors delivered by 
the implanted keratinocytes and its subsequent interactions with other cells, such as the dermal fibroblasts. It is 
known that keratinocytes produce Interleukin 1 (IL-1), Vascular Endothelial growth factors (VEGF), platelet-
derived growth factor (PDGF) and beta transforming growth factor (TGF- ), among others [10]. 
The upper levels of IL-1, combined with the environment’s tumor necrosis factor-alpha (TNF- ) are biomarkers 
of the inflammatory phase of the wound healing. They stimulate even more the local endothelial cells to increase 
the expression of cell adhesion molecules (CAMs). In this way, several blood cells migrate through the 
endothelium and reach the wound area. These cells include neutrophils and monocytes. The monocytes 
differentiate onto macrophages, which release other growth factors that help to induce the beginning of the 
proliferative phase. Besides that, it is known that IL-1 induces fibroblasts to produce and secrete growth factors 
such as keratinocyte growth factor (KGF), fibroblast growth factor 7 (FGF7) and interleukin 6 (IL-6) [10, 11, 12]. 
In this regard, the application of the autologous keratinocytes with autologous fibrin glue might have accelerated 
the healing process.  
The other growth factors secreted by the keratinocytes could also be involved in the better wound healing 
showed in this study. The VEGF induces angiogenesis, which is responsible for the formation of the granulation 
tissue, enhancing the new entered proliferative phase [10, 11]. The application of autologous keratinocytes might 
have increased the levels of VEGF, which could have altered positively the number of neo-synthetized vasculature 
vases. This could also be involved in the greater healing of the chronic venous ulcers in G1. 
In the proliferative phase, the PDGF also plays an important role. Right after the tissue injury the levels of 
PDGF increase because of the platelets degranulation. Later it is locally synthetized, and keratinocytes may be 
involved in this production, once these cells do produce PDGF and once it can be detected in the epithelium. 
According to Eming et al, the overexpression of PDGF-A promotes a faster fibro-vascular ingrowth and also cause 
deposition of mouse collagen type I. This probably happened because the collagen type I is the most abundant 
collagen fiber of the connective tissue [12, 13]. 
Another important growth factor secreted by keratinocytes is the TGF- . It is related to the cellular proliferation 
and migration, especially in wound healing. Studies show that in the first moment of the healing process the 
keratinocytes of the wound limits migrate towards it, reaching its center, while the fibroblasts do not proliferate nor 
migrate at this period. The migration of keratinocytes happens within hours, while the migration of fibroblasts do 
not happen until days after the injury has happened. Among other factors, this delay is also due to the different 
actions of the TGF-  in these cells: It is known that TGF-  inhibits proliferation and migration of fibroblast and 
the proliferation keratinocytes only.  Co-cultured keratinocytes and fibroblasts show an overexpression of TGF- . 
The wounds in  G1 could have had their TGF-  levels higher than the wounds in G2, which is very likely to have 
enhanced its healing process [12, 14, 15].  
Lis et al (2012) studied the use of cultured keratinocytes suspension in fibrin glue on the healing of oral mucosa 
wounds surgically produced using a rabbit model. Those authors concluded that the suspension of cultured 
autologous oral keratinocytes in fibrin glue significantly accelerates oral wound healing in the rabbit model and 
could be beneficial in the treatment of oral wounds in patients. According to these researchers, this data showed the 
direct effect of cells and their growth factors spread on the ulcer bottoms activating the indolent wounds and 
stimulating their healing [16]. 
Myers remarked that the keratinocyte-derived factors are essential to various stages of wound healing, such as 
inflammation, cell migration, matrix deposition, and maturation. This action can be explained taking into 
consideration the cytokines produced by these cells. In addition, considering the high morbidity of chronic venous 
ulcers in both groups, the results showed the relevant efficacy of cell therapy with autologous keratinocytes applied 
with fibrin glue scaffold achieving high rates of healing since the thirtieth day of follow-up becoming higher until 
the ninetieth day. In contrast, the fibrin glue alone applied in G2 did not improve the wound healing significantly, 
even receiving the greatest number of procedures [17].  
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5. Conclusion 
Cell therapy is efficient in the treatment of chronic venous ulcers that do not respond to usual treatments. 
Autologous keratinocytes applied with autologous fibrin glue promotes greater healing of chronic venous ulcers 
than fibrin glue only, especially in ulcers that do not respond to conventional treatment. 
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